Features April 2013 Issue

New Class of Cholesterol-Lowering Drugs Shows Promise

Taking a different path, PCSK9 Inhibitors reduce LDL cholesterol in statin-intolerant patients.

For patients who are unable to reap cholesterol-lowering benefits from the drugs known as statins due to intolerable side effects, technology may soon offer an alternative and effective treatment. While statins, including the most commonly used atorvastatin (Lipitor), simvastatin (Zocor) and rosuvastatin (Crestor) are the first line of treatment for reducing levels of the artery-clogging fatty deposits that increase “bad” cholesterol (LDL) levels, a new class of drugs may provide an unmet need in cholesterol-lowering alternatives, according to Michael Rocco, MD, Medical Director of Cardiac Rehabilitation and Stress Testing and staff cardiologist at Cleveland Clinic.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.